sexual function in patients with pcos andor obesity before and after metformin treatmentpcos患者的性功能和或肥胖之前和之后的二甲双胍治疗.pdf

Advances in Sexual Medicine , 2012, 2, 25-29 25 /10.4236/asm.2012.22005 Published Online April 2012 (http://www.SciRP.org/journal/asm) Sexual Function in Patients with PCOS and/or Obesity before and after Metformin Treatment Antoaneta Gateva, Zdravko Kamenov University Hospital Alexandrovska, Medical University of Sofia, Sofia, Bulgaria Email: tony_gateva@ Received January 10, 2012; revised February 12, 2012; accepted March 1, 2012 ABSTRACT The clinical signs of hyperandrogenemia, commonly seen in polycystic ovarian syndrome (PCOS) patients combined with obesity and infertility can cause emotional distress. There are however few data about the psychosocial and sexual function of patients with PCOS. Objectives: The aim of the study was to investigate the sexual function in patients with obesity and/or PCOS using Female sexual function inventory (FSFI) before and after metformin treatment. Design and Methods: In the present study were included 79 patients divided into three groups—group 1 Obese (n = 22); group 2 Lean PCOS (n = 41) and group 3 Obese PCOS (n = 16). All of the subjects completed FSFI questionnaire. In patients who had insulin resistance (OGTT + IRI) metformin treatment was started in dose 1700 - 3000 mg/day. Results: Obese women without PCOS showed significantly higher scores on total FSFI and all domains except from desire compared to lean PCOS subjects. Although the differences do not reach statistical significance, lean PCOS patients have the lowest scores on all domains. FSFI score correlates negatively only with androstendione levels. Women with and without hy- perandrogenemia do not show differences in FSFI score. It is interesting to note that LH but not FSH sho